Timing matters: study probes speed of blood thinner in lung clot patients

NCT ID NCT06912009

Recruiting now Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 adults hospitalized in the ICU for a serious pulmonary embolism (a blood clot in the lung). Researchers want to know how long it takes for the blood thinner (unfractionated heparin) to reach a level that prevents more clots. They will also check if faster blood thinning is linked to lower death rates, fewer repeat clots, or more bleeding. The goal is to improve how doctors start and monitor this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: unfractionated heparin (UFH)
What this could lead to: If successful, this could help doctors understand the best way to start blood thinners quickly in ICU patients with pulmonary embolism, potentially improving survival and reducing complications.
What could go wrong: This is a small, single-center, retrospective study, so results may not apply to all hospitals or patients. It only looks at past data, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMBOLISM

Contacts and locations

Locations

Service de Réanimation Médicale - CHU de Strasbourg - France
RECRUITING

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.